Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANDA trial of neoadjuvant atezolizumab plus capecitabine, oxaliplatin, and docetaxel in resectable gastric or gastroesophageal junction adenocarcinoma
NL-OMON50269Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, capecitabine, oxaliplatin and docetaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Netherlands Cancer Institute. Primary endpoints: Safety and Feasibility. Started Apr 2018; status: recruiting.
02
Drugs
atezolizumabcapecitabineoxaliplatindocetaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON50269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50269.